Cited 1 times in
Daratumumab plus bortezomib, cyclophosphamide, and dexamethasone in Asian patients with newly diagnosed AL amyloidosis: subgroup analysis of ANDROMEDA
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김진석 | - |
dc.date.accessioned | 2024-01-03T00:13:30Z | - |
dc.date.available | 2024-01-03T00:13:30Z | - |
dc.date.issued | 2023-04 | - |
dc.identifier.issn | 0939-5555 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/197195 | - |
dc.description.abstract | Subcutaneous daratumumab plus bortezomib/cyclophosphamide/dexamethasone (VCd; D-VCd) improved outcomes versus VCd for patients with newly diagnosed immunoglobulin light-chain (AL) amyloidosis in the phase 3 ANDROMEDA study. We report a subgroup analysis of Asian patients (Japan; Korea; China) from ANDROMEDA. Among 388 randomized patients, 60 were Asian (D-VCd, n = 29; VCd, n = 31). At a median follow-up of 11.4 months, the overall hematologic complete response rate was higher for D-VCd versus VCd (58.6% vs. 9.7%; odds ratio, 13.2; 95% confidence interval [CI], 3.3-53.7; P < 0.0001). Six-month cardiac and renal response rates were higher with D-VCd versus VCd (cardiac, 46.7% vs. 4.8%; P = 0.0036; renal, 57.1% vs. 37.5%; P = 0.4684). Major organ deterioration progression-free survival (MOD-PFS) and major organ deterioration event-free survival (MOD-EFS) were improved with D-VCd versus VCd (MOD-PFS: hazard ratio [HR], 0.21; 95% CI, 0.06-0.75; P = 0.0079; MOD-EFS: HR, 0.16; 95% CI, 0.05-0.54; P = 0.0007). Twelve deaths occurred (D-VCd, n = 3; VCd, n = 9). Twenty-two patients had baseline serologies indicating prior hepatitis B virus (HBV) exposure; no patient experienced HBV reactivation. Although grade 3/4 cytopenia rates were higher than in the global safety population, the safety profile of D-VCd in Asian patients was generally consistent with the global study population, regardless of body weight. These results support D-VCd use in Asian patients with newly diagnosed AL amyloidosis. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Springer International | - |
dc.relation.isPartOf | ANNALS OF HEMATOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols / adverse effects | - |
dc.subject.MESH | Bortezomib / adverse effects | - |
dc.subject.MESH | Cyclophosphamide / adverse effects | - |
dc.subject.MESH | Dexamethasone / adverse effects | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Immunoglobulin Light-chain Amyloidosis* / drug therapy | - |
dc.subject.MESH | Immunoglobulin Light-chain Amyloidosis* / etiology | - |
dc.subject.MESH | Multiple Myeloma* / drug therapy | - |
dc.title | Daratumumab plus bortezomib, cyclophosphamide, and dexamethasone in Asian patients with newly diagnosed AL amyloidosis: subgroup analysis of ANDROMEDA | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Kenshi Suzuki | - |
dc.contributor.googleauthor | Ashutosh D Wechalekar | - |
dc.contributor.googleauthor | Kihyun Kim | - |
dc.contributor.googleauthor | Chihiro Shimazaki | - |
dc.contributor.googleauthor | Jin Seok Kim | - |
dc.contributor.googleauthor | Takayuki Ikezoe | - |
dc.contributor.googleauthor | Chang-Ki Min | - |
dc.contributor.googleauthor | Fude Zhou | - |
dc.contributor.googleauthor | Zhen Cai | - |
dc.contributor.googleauthor | Xiaonong Chen | - |
dc.contributor.googleauthor | Shinsuke Iida | - |
dc.contributor.googleauthor | Nagaaki Katoh | - |
dc.contributor.googleauthor | Tomoaki Fujisaki | - |
dc.contributor.googleauthor | Ho-Jin Shin | - |
dc.contributor.googleauthor | NamPhuong Tran | - |
dc.contributor.googleauthor | Xiang Qin | - |
dc.contributor.googleauthor | Sandra Y Vasey | - |
dc.contributor.googleauthor | Brenda Tromp | - |
dc.contributor.googleauthor | Brendan M Weiss | - |
dc.contributor.googleauthor | Raymond L Comenzo | - |
dc.contributor.googleauthor | Efstathios Kastritis | - |
dc.contributor.googleauthor | Jin Lu | - |
dc.identifier.doi | 10.1007/s00277-023-05090-z | - |
dc.contributor.localId | A01017 | - |
dc.relation.journalcode | J00161 | - |
dc.identifier.eissn | 1432-0584 | - |
dc.identifier.pmid | 36862168 | - |
dc.subject.keyword | Asian | - |
dc.subject.keyword | Body weight | - |
dc.subject.keyword | Daratumumab | - |
dc.subject.keyword | Efficacy | - |
dc.subject.keyword | Light-chain amyloidosis | - |
dc.subject.keyword | Safety | - |
dc.contributor.alternativeName | Kim, Jin Seok | - |
dc.contributor.affiliatedAuthor | 김진석 | - |
dc.citation.volume | 102 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 863 | - |
dc.citation.endPage | 876 | - |
dc.identifier.bibliographicCitation | ANNALS OF HEMATOLOGY, Vol.102(4) : 863-876, 2023-04 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.